Based in New Jersey, Becton, Dickinson and Company (BDX - Free Report) is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. These products are used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Currently, Becton, Dickinson has a Zacks Rank #3 (Hold) but that could change following its fourth-quarter fiscal 2016 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings: Becton, Dickinson’s adjusted earnings of $2.12 per share beat the Zacks Consensus Estimate by 3 cents and increased from $1.94 posted in the year-ago quarter on a currency-neutral basis.
Revenues: Adjusted revenues amounted to $3.23 billion, up 5.6% from the year-ago quarter on a comparable currency-neutral basis. Revenues beat the Zacks Consensus Estimate of $3.22 billion.
Key Stats: BD Medical generated revenues of $2.24 billion, up 7.3% on a year-over-year basis. BD Lifesciences generated revenues of $996 million, up 2.1% from the year-ago quarter. On a comparable basis, adjusted U.S. revenues increased 7.2%. International revenues increased 5.2% on a currency-neutral basis in the reported quarter.
Major Factors: BD Medical’s year over year growth reflects strong performance in the Medication Management Solutions, Pharmaceutical Systems and Diabetes Care units.
Revenue growth in the BD Lifesciences segment reflects strong performance in the Preanalytical Systems and Biosciences units.
Check back later for our full write up on this Becton, Dickinson and Company earnings report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Based in New Jersey, Becton, Dickinson and Company (BDX - Free Report) is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. These products are used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Currently, Becton, Dickinson has a Zacks Rank #3 (Hold) but that could change following its fourth-quarter fiscal 2016 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings: Becton, Dickinson’s adjusted earnings of $2.12 per share beat the Zacks Consensus Estimate by 3 cents and increased from $1.94 posted in the year-ago quarter on a currency-neutral basis.
Revenues: Adjusted revenues amounted to $3.23 billion, up 5.6% from the year-ago quarter on a comparable currency-neutral basis. Revenues beat the Zacks Consensus Estimate of $3.22 billion.
Key Stats: BD Medical generated revenues of $2.24 billion, up 7.3% on a year-over-year basis. BD Lifesciences generated revenues of $996 million, up 2.1% from the year-ago quarter. On a comparable basis, adjusted U.S. revenues increased 7.2%. International revenues increased 5.2% on a currency-neutral basis in the reported quarter.
Major Factors: BD Medical’s year over year growth reflects strong performance in the Medication Management Solutions, Pharmaceutical Systems and Diabetes Care units.
Revenue growth in the BD Lifesciences segment reflects strong performance in the Preanalytical Systems and Biosciences units.
Check back later for our full write up on this Becton, Dickinson and Company earnings report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on BDX - FREE